本帖最后由 老马 于 2012-1-13 21:20 编辑 5 p3 } R1 L7 D
; N( p4 m$ s7 q3 n& V7 a% |: u爱必妥和阿瓦斯丁的比较. E5 h2 t. Y5 Z1 r7 D( Y0 ?/ k
2 F4 E5 k5 r0 S: l
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
7 j- \; i5 U: N# d
( U, V) `( @& L
& J3 [' o0 }; b; a
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/; b0 Y: \. I) R8 Z- y
==================================================: s) X+ c4 Y }( S7 j/ C/ ?/ w
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
7 K5 y+ B6 L1 a4 v0 Z: zPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
4 f$ h1 X) u% r2 p0 x% MResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.2 ?% ?( U: |! B& y& m& z
|